ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.
Company profile
Ticker
IDYA
Exchange
Website
CEO
Yujiro Hata
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
474268251
IDYA stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
31 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
12 Mar 24
S-8
Registration of securities for employees
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
20 Feb 24
8-K
Other Events
23 Jan 24
Transcripts
Latest ownership filings
4
TERRY J ROSEN
31 May 24
4
Susan L. Kelley
31 May 24
4
Malcolm Garret Hampton
31 May 24
4
Jeffrey Stein
31 May 24
4
Scott W Morrison
31 May 24
4
WENDY L YARNO
31 May 24
4
CATHERINE J MACKEY
31 May 24
4
MICHAEL ANTHONY WHITE
31 May 24
144
Notice of proposed sale of securities
29 May 24
4
Yujiro S Hata
16 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 109.10 mm | 109.10 mm | 109.10 mm | 109.10 mm | 109.10 mm | 109.10 mm |
Cash burn (monthly) | 16.22 mm | (no burn) | 17.01 mm | 13.26 mm | 14.60 mm | 10.93 mm |
Cash used (since last report) | 33.54 mm | n/a | 35.16 mm | 27.42 mm | 30.19 mm | 22.60 mm |
Cash remaining | 75.56 mm | n/a | 73.95 mm | 81.68 mm | 78.91 mm | 86.50 mm |
Runway (months of cash) | 4.7 | n/a | 4.3 | 6.2 | 5.4 | 7.9 |
Institutional ownership, Q1 2024
14.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 26 |
Closed positions | 75 |
Increased positions | 17 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 161.57 bn |
Total shares | 10.80 mm |
Total puts | 6.00 k |
Total calls | 22.50 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 2.46 mm | $39.06 mm |
BMY Bristol-Myers Squibb | 1.63 mm | $11.07 mm |
WuXi Healthcare Ventures II | 1.40 mm | $10.52 mm |
5AM Ventures IV | 1.20 mm | $27.87 mm |
Fiera Capital | 1.09 mm | $47.80 bn |
Candriam Luxembourg S.C.A. | 630.02 k | $27.65 bn |
First Turn Management | 397.78 k | $17.45 bn |
New York State Common Retirement Fund | 323.42 k | $14.19 mm |
Victory Capital Management | 286.51 k | $12.57 bn |
Jennison Associates | 256.25 k | $11.24 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 May 24 | Catherine J Mackey | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Hampton Malcolm Garret | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Rosen Terry J | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Kelley Susan L. | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Stein Jeffrey | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
News
Goldman Sachs Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $46
13 May 24
Unveiling 5 Analyst Insights On IDEAYA Biosciences
8 May 24
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target
8 May 24
IDEAYA Biosciences Q1 2024 GAAP EPS $(0.53), Inline
7 May 24
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
24 Apr 24
Press releases
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 May 24
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
29 May 24
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
28 May 24
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
23 May 24
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
7 May 24